A Phase 2/3 interventional study of GLM101 (Part A, Double-blind) and Placebo (Part A, Double-blind) in Phosphomannomutase 2 Deficiency and PMM2-CDG, sponsored by Glycomine, Inc.. Active, not recruiting at 15 sites in 10 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Glycomine, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Ataxia with a site in United States — 18 open to participants now, 20 under way, 1 of them phase 3. Ataxia · United States.
Among the 63 studies in Ataxia with a site in United States, this one is the 12th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 2 of the 19 other live ones, and was the 56th registered.
149 studies on the registry are indexed under Ataxia; 37 are open to participants now.
Browse Ataxia studies →18 of the 63 studies in Ataxia with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 6 mo+
The POLG Foundation · Sites in United States, Australia, Denmark and 6 more countries
Johns Hopkins University · Sites in United States
Ages 18–80 · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Solid Biosciences Inc. · Sites in United States
Ages 18–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Ataxia studies recruiting now, 13 (46%) set no upper age limit and 12 (43%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 9 · Phase 3 2
First in 1992; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 30 across 100 interventional studies indexed under Ataxia.
Median enrollment 23 across the 42 interventional studies, 214 across the 20 observational. Of the 36 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 63 have an industry lead sponsor. The 10 most frequent:
Glycomine, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Glycomine, Inc. has 1 study filed under Ataxia — fewer than ten, so there is no comparison to draw.
4 of the studies in Ataxia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05807321The California Medical Innovations Institute, Inc.Fecobionics in Biofeedback Therapy in Dyssynergia Patients | 2027-01-01 |
| NCT02841553Washington University School of MedicineWolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study | 2027-04 |
| NCT07845825The University of Texas Health Science Center at San AntonioAprepitant for the Treatment of CLIFAHDD | 2027-05-31 |
| NCT02316314Weill Medical College of Cornell UniversityCharacterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 63 studies in Ataxia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG.
The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).
This Phase 2b, multicenter, randomized, double-blind, placebo-controlled clinical study is designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric participants with PMM2-CDG. The study is structured into: a 4-week Screening Period, a 24-week Double-blind Treatment Period (Part A) to assess primary efficacy, a 24-week Open-label Extension Period (Part B), and a safety follow-up visit conducted 4 weeks after the last infusion. In Part A, participants will be randomly assigned to receive weekly intravenous infusions of either GLM101 at 30 mg/kg or a placebo for 24 weeks. After the end of Part A, participants will transition into Part B, a 24-week open-label extension where all participants will receive GLM101. The primary objective of the trial is to identify changes from baseline in coordination and muscle movement (ataxia) using the International Co-operative Ataxia Rating Scale (ICARS) after 24 weeks of taking GLM101 compared to a placebo in PMM2-CDG patients.
Inclusion criteria: Participant is eligible for participation in the study if all of the following apply:
Male or female participant has appropriate measures in place to prevent pregnancy:
Exclusion criteria: Participant will be excluded from participation in the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GLM101 (Part A, Double-blind) · Drug: GLM101 (Part B, Open-label)
Drug: Placebo (Part A, Double-blind) · Drug: GLM101 (Part B, Open-label)
IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A
IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A
IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants
Evaluation of Ataxia Changes Using the International Cooperative Ataxia Rating Scale (ICARS) in PMM2-CDG Patients at 24 weeks
To characterize the change from Baseline in ataxia at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by ICARS. The scale is scored out of 100 with 19 items and four subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment (Part A).
Time frame: At baseline and at week 24.
Evaluation of Change from Baseline in Gross Motor Function at 24 Weeks Using the Neuromuscular Gross Motor Outcome (GRO) in PMM2-CDG Patients
To characterize the change from Baseline in gross motor function at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by GRO. The GRO is a gross neuromuscular motor outcome measure designed to assess whole body strength, motor development, and function for all levels of ability across the lifespan (Part A).
Time frame: At baseline and at week 24.
Evaluation of Change from Baseline in Ataxia at 24 Weeks Using the Scale for the Assess and Rating of Ataxia (SARA) in PMM2-CDG Patients
To characterize the change from Baseline in ataxia at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by SARA. It consists of eight items of patient performance including gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, and heel-shin slide. It is scored out of 40 points with higher scores indicating higher levels of impairment (Part A).
Time frame: At baseline and at week 24.
Evaluation of Change in Global Impression of Improvement/Changes and Severity at 24 Weeks by PMM2-CDG Patients, Caregiver and Physician
To evaluate the participant, caregiver, and physician global impression of improvement/change and severity at 24 weeks, comparing GLM101 to placebo (Part A).
Time frame: At baseline and at week 24.
Reporting of Adverse Events (AEs) in PMM2-CDG Patients at 24 weeks (Part A)
Time frame: At baseline and up to week 24.
Reporting of Blood Pressure in PMM2-CDG Patients at 24 weeks (Part A)
Blood pressure will be measured in millimeters of mercury (mmHg).
Time frame: At baseline and up to week 24.
Reporting of Body Temperature in PMM2-CDG Patients at 24 weeks (Part A)
Body Temperature will be measured in degree Celsius (°C).
Time frame: At baseline and up to week 24.
Reporting of Pulse Rate in PMM2-CDG Patients at 24 weeks (Part A)
Pulse rate will be measured in beats per minute (bpm).
Time frame: At baseline and up to week 24.
Reporting of Respiratory Rate in PMM2-CDG Patients at 24 weeks (Part A)
Respiratory rate will be measured in breaths per minute.
Time frame: At baseline and up to week 24.
Reporting of Cardiovascular Health Using Electrocardiogram (ECG) in PMM2-CDG Patients at 24 weeks (Part A)
The following parameters will be evaluated: heart rate, PR, RR, QRS, QT intervals along with information on T and U-wave morphology.
Time frame: At baseline and up to week 24.
Evaluation of Ataxia Changes Using the International Cooperative Ataxia Rating Scale (ICARS) in PMM2-CDG Patients from baseline to the End of the Study
To evaluate the effect of GLM101 on changes in ICARS score to the end of study. The objective is to evaluate ICARS changes over 48 weeks, comparing early versus delayed GLM101 treatment, placebo-to-GLM101 transitions, and visit-wise changes in participants receiving GLM101 (Part B).
Time frame: At baseline and at weeks 24 and 48.
Evaluation of Changes in the Neuromuscular Gross Motor Outcome (GRO) Score in PMM2-CDG Patients from baseline to the End of the Study
To evaluate the effect of GLM101 on changes in GRO score to the end of study. The objective is to evaluate changes in GRO score over 48 weeks, comparing early versus delayed GLM101 treatment, placebo-to-GLM101 transitions, and visit-wise changes in participants receiving GLM101 (Part B).
Time frame: At baseline and at weeks 24 and 48.
Evaluation of Changes in the Scale for the Assess and Rating of Ataxia (SARA) Score in PMM2-CDG Patients from baseline to the End of the Study
To evaluate the effect of GLM101 on change in SARA score to the end of study. The objective is to evaluate changes in SARA Score over 48 weeks, comparing early versus delayed GLM101 treatment, placebo-to-GLM101 transitions, and visit-wise changes in participants receiving GLM101 (Part B).
Time frame: At baseline and at weeks 24 and 48.
Evaluation of Change in Global Impression of Improvement/Changes and Severity from baseline to the End of the Study by PMM2-CDG Patients, Caregiver and Physician
To evaluate the participant, caregiver, and physician global impression of improvement/change and severity up to 48 weeks of dosing with GLM101. Evaluation of visit-wise changes in participant, caregiver, and clinician impressions of change, severity, and improvement for overall, ataxia, and gross motor function (Part B).
Time frame: At baseline and up to week 48.
Reporting of Adverse Events in PMM2-CDG Patients from Baseline to the End of the Study (Part B)
Time frame: At baseline and up to week 48.
Reporting of Blood Pressure in PMM2-CDG Patients from Baseline to the End of the Study (Part B)
Blood pressure will be measured in millimeters of mercury (mmHg).
Time frame: At baseline and up to week 48.
Reporting of Pulse Rate in PMM2-CDG Patients from Baseline to the End of the Study (Part B)
Pulse rate will be measured in beats per minute (bpm).
Time frame: At baseline and up to week 48.
Reporting of Body Temperature in PMM2-CDG Patients from Baseline to the End of the Study (Part B)
Body Temperature will be measured in degree Celsius (°C).
Time frame: At baseline and up to week 48.
Reporting of Respiratory Rate in PMM2-CDG Patients from Baseline to the End of the Study (Part B)
Respiratory rate will be measured in breaths per minute.
Time frame: At baseline and up to week 48.
Reporting of Cardiovascular Health Changes Using Electrocardiogram (ECG) in PMM2-CDG Patients from Baseline to the End of the Study (Part B)
The following parameters will be evaluated: heart rate, PR, RR, QRS, QT intervals along with information on T and U-wave morphology.
Time frame: At baseline and up to week 48.
Maximum Concentration (Cmax) of Mannose-1-phosphate (M1P) in PMM2-CDG Patients as Key PK Parameter over 48 weeks to the End of the Study (Part B)
Cmax will be estimated using Blood Samples collected Pre- and Post-Infusion.
Time frame: At Baseline and at weeks 11, 12, 20, 21, 35, 36, 44, 45.
Time from dosing to the Maximum Concentration (tmax) of Mannose-1-phosphate (M1P) in PMM2-CDG Patients as Key PK Parameter over 48 weeks to the End of the Study (Part B)
tmax will be estimated using Blood Samples collected Pre- and Post-Infusion.
Time frame: At Baseline and at weeks 11, 12, 20, 21, 35, 36, 44, 45.
Area under the concentration versus time curve (AUC) of Mannose-1-phosphate (M1P) in PMM2-CDG Patients as Key PK Parameter over 48 weeks to the End of the Study (Part B)
AUC will be estimated using Blood Samples collected Pre- and Post-Infusion.
Time frame: At Baseline and at weeks 11, 12, 20, 21, 35, 36, 44, 45.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Aug 2026, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLM101
Glycomine, Inc.